For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Century-old drug repurposed to fight ulcers in cancer, diabetic patientson May 11, 2020 at 9:01 am
Suramin, a 100-year old drug used to treat sleeping sickness, has been repurposed to fight oral mucositis and diabetic foot ulcers.
- AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patientson May 11, 2020 at 6:00 am
PRNewswire/ -- A recent study of metastatic breast cancer (MBC) patients, prescribed a class of drugs that interrupt malignant cell growth, revealed ...
- Toxin-inspired platform could improve the delivery of RNA therapeuticson May 7, 2020 at 6:02 am
Researchers have developed a novel drug delivery platform utilizing a modified diphtheria toxin for improved efficiency of RNA therapeutics.
- UVA developing new tools to battle neurological diseases, cancer, strokeon May 7, 2020 at 5:42 am
UVA researchers hope a new approach could revolutionize treatment for conditions from Alzheimer’s to epilepsy to brain tumors.
- Drug Delivery Devices Market Anticipated to Cross $345.8 Billion By 2027 | Grand View Research, Incon May 7, 2020 at 4:07 am
The global drug delivery devices market size is expected to reach USD 345.8 billion by 2027, expanding at a CAGR of 6.15% over the forecast period, according to a new report by Grand View Research, ...
- Injectable Drug Delivery Market Prominent Players: SHL Group AB , BD, Insulet Corporation, Pfizer, Eli Lilly and Company, Others Forecast to 2026on May 6, 2020 at 10:37 pm
The rising prevalence of chronic diseases such as diabetes, cancer, and others is boosting the global “Injectable Drug Delivery Market”. Fortune Business Insights in a report, titled “INJECTABLE DRUG ...
- "Corkscrew” microrobots skewer cancer cells for targeted drug deliveryon May 6, 2020 at 8:39 pm
In the not too distant future, tiny robots could be delivering drugs inside our bodies, but there are still a few hurdles to clear before we realize that scenario. Now researchers have developed ...
- The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019on May 6, 2020 at 8:19 pm
... the largest share by product owing to the high efficacy of the drug exhibited in the treatment of cancer.Moreover, the liposomal doxorubicin is beneficial over its traditional counterparts in ...
- 3M completes $650M drug delivery unit sale, but business to remain in Twin Citieson May 5, 2020 at 12:22 pm
The new entity owned by Altaris Capital Partners will be called Kindeva Drug Delivery and continue to operate its R&D lab and a manufacturing facility on 3M's Maplewood campus for about a year, Aaron ...
via Bing News